แนวทางการดูแฉรักษาผู้ป่วยเบาหวานในปัจจุบัน

Expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.

International expert committee. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327-34.

American Diabetes Association. Standards of medical care in Diabetes 2013 (position statement). Diabetes Care 2013; 36: S11- 66.

Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. Intema-tional association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglyccomia in pregnancy.Diabetes Care 2010;33:676-82.

HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Eng J Med 2008; 358: 1991-2002.

Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: 3160-7.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62-69.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with the lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.

The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and preogression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.

Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow up of intensive glucose control in type 2 diabetes. N Eng J Med 2008; 359: 1577-89.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern day clinical course of type 1 diabetes mellitus after 30 years' duration: the DCCT/EDIC and Pittsburg epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169: 1307-16.

ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.

Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intervention diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.

Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R, et al. Intensive glucose lowering therapy. reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009; 59: 2642-48.

เป้าหมายการรักษา การติดตาม การประเมินผลการรักษาและการส่งปรึกษา. แนวทางเวชปฏิบัติสำหรับโรคเบาหวาน พ.ศ. 2554. สมาคมโรคเบาหวานแห่งประเทศไทย สมาคมโรคต่อมไร้ท่อแห่งประเทศไทย และสำนักงานหลักประกันสุขภาพแห่งชาติ. กรุงเทพมหานคระศรีเมืองการพิมพ์;2554. หน้า 39-45.

Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al. Summary and recommendations of the fifth international workshop-conference on gestational diabetes mellitus. Diabetes Care 2007; 30: S251-S260.

Kitzmiller JL, Block JM, Brown FM, Catalano PM, Con-way DI, Coustan DR, et al. Mananging preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 2008; 31: 1060-79.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, al. Management ofhyperglycemia in type 2 diabetes: a patient-centered approach: a position statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2012: 35:1364-79.

Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-7.

Ismail-Beigi F. Glycemic management of type 2 diabetes mellitus. N Eng J Med 2012; 366: 1319-27.

การให้ย'เพื่อควบคุมระดับน้ำตาลในเลือดในผู้ใหญ่..แนวทางเวชปฏิบัติสำหรับโรคเบาหวาน พ.ศ. 2554. สมาดมโรคเบาหวานแห่งประเทศไทย สมาคมโรคต่อมไร้ท่อแห่งประเทศไทย และสำนักงานหลักประกันสุขภาพแห่งชาติ. กรุงเทพมหานคร: ศรีเมืองการพิมพ์; 2554 หน้า 25-34.

ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-85.

ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovas:ular and microvascular outcomes in patients with type 2 diabetes mellitus. Lancet 2007; 370:829-40.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detion, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The Seven Report of the Joint National Commitee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC7 report. JAMA 2003;289:256)-72.

Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) inpatients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.

he ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA 2002;288:2981-97.

Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007; 3: 428-38.

Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996; 335: 257-65.

Heart Protection Study Collaborative Group: MRH/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placcbo-controlled trial. Lancet 2003; 361: 2005-16.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.

Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-2.

WolffT,Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S.Preventive Services Task Force. Ann Intem Med 2009; 150: 405-10

US Prevention Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150; 396-404.

Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidrogel versus aspirin in patients with diabetes mellitus. Am I Cardiol 2002; 90: 625-8.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.

Heart Outcomes Prevention Evaluation Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345: 851-60.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.

ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.

Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28:956-62.

Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, et al. American Diabetes Association, American Association of Clinical Endocrinologists. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical 13 Endocrinologists. Diabetes Care 2008; 31: 1679-85.

American Diabetes Association: Peripheral arterial disease in people with diabetes (Consensus Statement). Diabetes Care 2003; 26: 33333-41.